The Bioclinic Group

About The Bioclinic Group

The Bioclinic Group operates as a significant network of medical biology laboratories primarily located in the Île-de-France region. Founded in 1995 by Dr. Philippe Dabi, the company has established itself as a key player in the French medical diagnostics market. Dr. Dabi, who has been the majority shareholder and president since its inception, has guided the group through a consistent growth trajectory, demonstrating expertise in acquiring and integrating new laboratory sites within a consolidating market.

The company's core business revolves around providing a comprehensive range of medical analysis services. Its specializations include molecular biology, infectious diseases, genetics, assisted procreation, and cytopathology. Bioclinic serves a diverse client base that encompasses individual patients, hospitals, clinics, care centers, and retirement homes. Revenue is generated by performing these diagnostic tests, which are crucial for patient care, contributing to a large percentage of medical diagnoses.

Bioclinic's strategic approach has heavily focused on expansion through both organic growth and a robust strategy of external acquisitions. A notable period of acceleration occurred between 2011 and 2018, with the support of financial partners Azulis Capital and Galia Gestion, leading to the acquisition of 34 sites. This strategy continued with further acquisitions, including Bioascogen, BIOMEGA Medical Biology Laboratories, and Laboratoire LCV between 2019 and 2021. This aggressive expansion solidified Bioclinic's position, operating nearly 100 laboratories in the Paris region by early 2021. In July 2022, the group was acquired by Inovie, a major French medical biology player, marking a new chapter in its development while retaining its operational and medical teams.